Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
raf, I think KM was in the way of Denner's future plans. KM may have been the reason why we lost Germany and AD saw right threw his blunders.
raf, question by Hikma selling .05 V will that still be considered infringement when scripted for CVD?
meowzo, J6 was NOT the saddest day 9/11/2001 I witnessed horror. J6 was a nothing burger. Watch the videos that were released which were withheld from the public.
AMRN will live to fight another day with Denner's guidance! He will save Vascepa from the hounds.
Raf, yes indeed. Question will be who will be CEO. I think Denner will pull a rabbit trick.
Invest, it's a sad day in America. The corrupt judicial system makes me sick.
invest, I'm not suggesting investing in any stock that is in the space just using it as an example. The justice system is broken.
invest, have you been watching what's going on in the diet drug sector, Ozempic, wegovy and several others are FDA approved for diabetes but many are being scripted for off label weight loss. If you take these drugs long enough you'll grow two heads! Even weight watchers recently purchased a private company, Sequence.
I've noticed a reduction in jobs posted on LinkedIn for the EU since Sarissa won the proxy contest. Cost cutting def going on. The info listed about the company states less than 500 employees.
This is just another example of total BS in advertising. WTF they don't even mention prescribed for lowering HT/LDL.
https://www.springmeds.com/productdetails/Vascepa-Icosapent-Ethyl?uidtype=group&form=Capsules&isGeneric=Y&strength=1gm
CBB, unfortunately, that's our current state of affairs. Wall Street hates indecision and a company with no direction. Until we learn more about the status of approvals as sales start to ramp up in the countries where we're approved we just have to wait. I still believe China is a lost cause.
I think we will see a different style of filing with some detail changes not fluff some items will be eliminated. I'm hoping they break down revenues from the US and EU. But we'll have to wait to see in the next quarterly filing.
BBI, sorry if you took offense. I honestly thought you were serious.
meowzo, why.... please explain. I assume you're very familiar with the subject.
BBI, if the EU doesn't have the "internet" then what form of communication and social media is available? I think they have access except in the communist controlled countries. Even in Ukraine they have starlink. They plan on having starlink available worldwide shortly.
Ref, Vascepa...excerpt from HLS annual report.
HLS Therapeutics Announces Q4 and Fiscal 2022 Financial Results
TORONTO, March 16, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces its financial results for the three- and twelve-month periods ended December 31, 2022. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.
Q4 & FISCAL 2022 FINANCIAL HIGHLIGHTS
• 2022 revenue of $61.5 million, Adjusted EBITDA of $23.8 million and cash-flow from operations of $16.9 million.
• Q4 2022 revenue was $15.7 million, up 4% to $16.4 million measured in constant currency.
• 2022 revenue was $61.5 million, up 5% to $63.0 million measured in constant currency.
• Q4 2022 Vascepa net revenue was C$3.6 million compared to C$2.4 million in Q4 2021, up 51%. In the near-term, Vascepa net revenue growth will trail growth in prescriptions as net pricing adjusts to additional public sector volumes.
• 2022 Vascepa net revenue was C$12.3 million compared to C$7.4 million in 2021; up 67%.
• Q4 2022 Adjusted EBITDA was $5.3 million compared to $6.2 million in Q4 2021.
• 2022 Adjusted EBITDA was $23.8 million compared to $26.3 million in 2021.
• Q4 2022 net loss was ($6.4) million, compared to net loss of ($4.2) million in Q4 2021.
• 2022 net loss was ($23.6) million, compared to net loss of ($13.1) million in 2021.
• Renewed the Company's Normal Course Issuer Bid ("NCIB"). Share repurchases in 2022 totaled $1.0 million.
• Extended and updated certain terms of the credit facility to provide additional capital flexibility.
Q4 & FISCAL 2022 OPERATIONAL HIGHLIGHTS
• 2022 total Vascepa prescription volumes ("TRx") grew 85% year-over-year and grew 22% sequentially in Q4 2022.
• 3,300 physicians have prescribed Vascepa, up 92% year-over-year.
• New Prescriptions ("NRx") increased 124% in Quebec and 67% in Ontario in Q4 2022 following recent public reimbursement listings.
• Expanded access to Vascepa by adding public reimbursement for more than 70% of publicly covered lives in Canada.
• Vascepa remains the fastest growing product amongst its competitive set on a monthly, quarterly and trailing twelve-month basis.
"In 2022, HLS delivered revenue growth with reliable cash flows and Adjusted EBITDA, while increasing investment in sales activities related to Vascepa," said Gilbert Godin, CEO of HLS. "On a constant currency basis, consolidated revenue for 2022 increased 5%, reflecting Vascepa's growing top-line contribution. Vascepa's net revenue grew 67% in 2022, also on a constant currency basis."
"We continue to see growing adoption rates for Vascepa which are reflected in the greater number of physicians and patients who are new to the product, particularly in Quebec and Ontario where Q4 NRx growth rates were 124% and 67%, respectively."
"While claims processing by the Quebec drug plan continues to improve resulting in a higher Vascepa growth rate, prescribers in Ontario are reporting a more burdensome public authorization process. We are working with the province to facilitate and simplify the onboarding of new public plan patients. We are confident this will further improve access for those who are at risk of cardiovascular disease."
"Vascepa is well-positioned with public and private reimbursement in place, standard-of-care endorsements from Canadian medical societies, greater access to physicians and fully operational field personnel. Our focus today is on maximizing access and physician interactions. The steady level of field activity in Q4 lays the groundwork for future adoption as increasing the frequency of calls to relevant physicians is essential to generate trial and adoption."
Mr. Godin continued: "Regarding other products in the portfolio, we have successfully maintained our leadership position for Clozaril in Canada at a time when the mental health settings of care have been under pressure. During this period, Clozaril has continued to generate steady and reliable financial results. In 2022, Clozaril revenue in Canada was essentially level year-over-year (on a constant currency basis) as the market continues to recover from the effect that the pandemic had on access to, and initiation of, refractory schizophrenic treatments. We continued the roll-out of CSAN Pronto and believe it will further strengthen our leadership position with Clozaril."
"And finally, we have met with Health Canada to discuss the positive results of the recent Spanish SECURE trial for Trinomia and expect to refile the product in the second half of this year. Trinomia combines three common medications in one daily pill for patients who have experienced a cardiac event. A polypill such as Trinomia can help improve medication compliance, which is important for reducing the likelihood of a subsequent cardiac event in such patients as evidenced in the Spanish trial."
VASCEPA OUTLOOK
In 2023, HLS expects Vascepa's net revenue to be in a range of C$22-28 million, starting with expected year over year growth of approximately 40-50% in Q1 2023. Growth rates for Vascepa are expected to increase as the year progresses as the frequency of contact with physicians continues and in-line with customary seaso
So where's our PR lady, Lisa??? Her name is no longer associated with the investor link. humm
kiwi, geez I hope you're wrong, that would be awful. I did find that back in 2012 there was some association with Credit Suisse cause of their ADR's but I sure hope that's not the case today. ;-(
dogn, much dissatisfaction with PWO on all fronts.
Kiwi, I hope you're assumption is correct.
shadolane, there was a block of almost 500,000 traded mid day. It's encouraging maybe someone thinks the stock is undervalued???
CBB, So the question I would ask is why would AD want to increase his stake in amrn? My guess is he would need more conviction to increase his stake too soon to think about that question. It depends on what he finds. If he suspects there's something down the road that would be a promising product to increase revs or an EU approval that starts generating revs eg UK then it's possible. If he decides to become COB then he's entitled to stock options-RSU's. I think we have to wait for the proxy to be filed which should be in a few months. In the meantime, he could nominate an interim COB until the proxy is filed.
I emailed Sarissa asking about where amarin keeps their funds but no reply. I'm hoping the FDIC doesn't drain all their funds supporting all the uninsured bank loans. It's scary times.
CBB, I believe it will take a while to determine where to cut the layers of non-productive employees to find their footing for each country etc. So many years of data and financials to sift through eg what's real and what's BS that KM has been flinging over the past couple of years. As an outsider, I can tell you there's soo much fluff in the financials that needs cleaning up such as the inventory. It's like the banks investing in long term notes and if marked to market they'd have to close half the banks. I think Sarissa is finding some surprises under the covers I just hope it's not too negative whatever it is.
Denner wants to save the liquid gold and the millions invested in the stock. Personally, I'm glad he has skin in the game. He's got a turnaround situation that will take time to unravel.
Sleven ref your find on Adis Insight, link is from an observer
Yes. AMR102 was combi-pill that succesfully cleared P1 studies before being paused for REDUCE-IT duration. It was a fixed-dose combination of Vascepa & rosuvastatin. Sounds like they will concentrate outside CV space as AMR-102 is really more of a "convenience item" per JT today.
— TerraPharma (@TerraPharma1) January 15, 2020
ramfan LOL
Just an FYI, for anyone who follows stock options sales and new disclosure rules. Effective 4/1/23
https://www.sec.gov/files/33-11138-fact-sheet.pdf
hello...has anyone noticed the blocks that have been traded today? Someone is accumulating some shs!
newman, I think the $50 is the fee to buy the PDF profile for the combo data.
meowzo, what has happened is the SigNet division of SBNY is not FDIC insured. It's a conduit to move crypto through their Signet division, it's so complicated. SEN was the most concentrated exchange used for moving money laundering etc after SI closing, therefore, the only other source that has a similar SEN platform is Signet a division of (SBNY). I think that's why the govt closed them down as it became systemic in a matter of hours. COIN, MSTR
how ironic is it that Barney Frank the original designer of the Dodd-Frank ruling after the 2008 failures is on the board of SBNY.
Signature Bank Closed By Regulators, Fed Announces Backstop To Safeguard Depositors
RSM, Yellen said no way José.
Meowzo, r u replying to my last post, if so do I mention crypto. No.... Or u making a statement that you think crypto was the cause of the demise of SVB? Can't follow your logic.
Sen & Signet r crypto related u should know that of course SBF is the MF'er fraudster sociopath of all. I'm sure you're familiar with The Albany.
Kiwi, I emailed sarissa asking amarin's cash and which banks they use. Hopefully that'll reply.
RMB, fairly accurate. The bank was shut down. According to Fdic law they're only obligated to pay out $250,000. Then depositors will have to stand in line for several years to see any money. Sad but true unless a consortium of HF or other finance entities decide to bail them out with iou's. Doubtful
meowzo, do you understand how SVB got to where it is/was until Friday? Go back to 2008 MBS's.
Please explain in a cogent statement why they have not learned their lesson. Low rates, concentration risk management red flag. Let's see if Monday brings hope for the VC's but if it's broken let it fail. Brings to mind Long Term Management.
newman, Dr. Sterling shares filed on the form 3 were part of the 210,000 which were purchased prior to the proxy contest. Eventually, when he files a form 4 they'll show up.
newman, form 3's are required by the SEC so the new directors can be assigned their own unique CIK number or a so called id# for future filings. Nothing more... it's not anything nefarious.
meowzo, 2 issues at hand here...rapid rate increases on one hand plus concentration. Crypto crooks on the other. The fallout will have a rippling effect across all industries. Black Swan event.
Actually, I emailed Sarissa asking about amarin's cash position and where do they bank hopefully not in the Bahama's!
IIRC, FFS suggested many months ago that amarin put their money in bitcoin. Yikes
meowzo, yeah that's only half the story the other half is money laundering, drug running, fictitious accounts and the affiliation with the mother of all frauds is SBF/FTX/FTT Alameda. Since SI collapsed the frauds are running to SBNY.
Form 3's being filed by new board members. It'll be interesting to see the form 4 filings containing info ref option and stock.